8-K: Inhibitor Therapeutics Secures $3M Private Placement

Inhibitor Therapeutics, Inc. entered into a Securities Purchase Agreement with an institutional investor for a $3 million private placement, issuing common stock and warrants.

Summary

• Inhibitor Therapeutics, Inc. (the "Company") entered into a Securities Purchase Agreement (SPA) on February 19, 2026, with an institutional investor for a $3,000,000 private placement.
• The Company agreed to sell 12,000,000 shares of its common stock and issue a Common Stock Purchase Warrant to purchase up to 7,000,000 additional shares of common stock.
• The purchase price for each unit (one common stock share and accompanying warrant) is $0.25.
• The warrants will be exercisable for a period of three years after issuance at an exercise price of $0.35 per share.
• If all warrants are exercised, it would result in additional gross proceeds of $2,450,000 to the Company.
• The proceeds from this financing are intended for working capital and general corporate purposes.
• The shares and warrant shares are subject to transfer restrictions under the Securities Act of 1933, unless registered or sold under an exemption.
• The investor also entered into a Lock-Up Agreement, restricting the sale or transfer of the acquired shares and warrant shares for nine months after the SPA execution date or until a Change in Control.
• As of February 24, 2026, the financing contemplated by the SPA has not yet closed and funded, but the Company expects it to close and fund within a reasonable period.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development. While the capital raise provides crucial funding for a pre-revenue company, the significant dilution and the lower price of the immediate share issuance compared to the warrant exercise price temper the overall positive sentiment.

Positives

• Secured $3,000,000 in new capital, providing essential funding for working capital and general corporate purposes for a pre-revenue, clinical stage company.
• The potential for an additional $2,450,000 in gross proceeds if the warrants are fully exercised, further strengthening the Company's financial position.

Negatives

• The issuance of 12,000,000 shares of common stock and warrants for up to 7,000,000 additional shares will result in significant dilution for existing shareholders.
• The purchase price of $0.25 per unit is below the warrant exercise price of $0.35, indicating a lower valuation for the immediate share issuance compared to future potential exercises.
• The financing has not yet closed and funded as of the filing date, introducing a short-term uncertainty regarding the receipt of funds.

Risks

• The Company is a pre-revenue, clinical stage venture with little current capital resources, making it highly dependent on successful capital raises.
• There is a material risk that the Company may be unable to raise any additional capital beyond this transaction, which could impact its operations and ability to continue as a going concern.
• The Purchased Securities and Warrant Shares are restricted and have not been registered under the Securities Act, limiting their liquidity for the investor.

Future Outlook

The Company intends to use the proceeds from this financing for working capital and general corporate purposes. It expects the financing to close and fund within a reasonable period of time following the February 24, 2026 filing date.

Management Comments

• The Company intends to use the proceeds received in connection with the Financing for working capital and general corporate purposes.

Industry Context

StockSavvy.ai notes that for pre-revenue, clinical-stage biopharmaceutical companies like Inhibitor Therapeutics, securing capital through private placements is a common and often critical mechanism to fund ongoing research, development, and operational expenses. Such financings are essential for extending the company's cash runway and advancing its pipeline, especially in an industry characterized by high R&D costs and long development timelines.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience dilution from the issuance of 12,000,000 new shares and potential further dilution from the exercise of 7,000,000 warrants. However, the capital raise provides necessary funding for the Company's operations, which could benefit long-term value.
• Investor: Gains a significant equity stake and warrants in the Company, subject to a 9-month lock-up period and transfer restrictions, indicating a long-term investment horizon.
• Company Operations: The $3,000,000 in proceeds will be used for working capital and general corporate purposes, directly supporting the Company's ability to continue its clinical development and operations.

Next Steps

• The Company expects the financing to close and fund within a reasonable period of time following the February 24, 2026 filing date.

Key Dates

Keywords

private placement, securities purchase agreement, common stock, warrants, capital raise, dilution, lock-up agreement, working capital, biopharmaceutical, clinical stage